comparemela.com

Latest Breaking News On - Aurinia lupkynis - Page 1 : comparemela.com

In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning

Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the management

United statesAurinia lupkynisAstrazeneca saphneloMaxine yarnall spherixEuropean unionSpherix networkGlobal insightsPatient chart dynamixRealworld dynamixChart dynamixSpherix global insightsSpherix global insightYarnall spherix global insightsSystemic lupus erythematosusLupus nephritisKidney disease

New Research on Emerging Cutaneous Lupus Erythematosus (CLE) Market Reveals Vast Potential for Pipeline Agents, According to Spherix Global Insights

/PRNewswire/ According to the Lupus Foundation of America, approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus.

United statesScott uphamAurinia lupkynisBristol myer squibb sotyktuBryan rexAstrazeneca saphneloCorporate communicationsSpherix networkLupus foundation of americaLupus foundationGlobal insightMarket dynamixCutaneous lupus erythematosusBristol myer squibbGlobal insightsSpherix global insights

Major Shifts in Management of Patients with Lupus Nephritis Spurred by Availability of Aurinia Pharmaceutical s Lupkynis and GSK s Benlysta, According to Spherix Global Insights

/PRNewswire/ With the approvals of GlaxoSmithKline s Benlysta (belimumab) in lupus nephritis (LN) at the end of 2020 and Aurinia s Lupkynis (voclosporin) at.

Novarti cosentyxAstrazeneca saphneloGlaxosmithkline benlystaScott uphamRoche genentech gazyvaAurinia lupkynisBryan rexJanssen tremfyaCorporate communicationsSpherix networkSpherix global insightsGlobal insightsRealworld dynamixLupus nephritisVera therapeuticWorld dynamix

European Lupus Market Coverage Highlights Pipeline Perceptions and Country Differences in Patient Management, Spherix Reports

/PRNewswire/ Rheumatologists have long struggled to effectively treat patients with systemic lupus erythematosus (SLE) given the wide heterogeneity of the.

United kingdomAstrazeneca saphneloAurinia lupkynisGlaxosmithkline benlystaBryan rexRoche gazyvaNational institute for healthBristol myers squibbGlobal insightsMarket dynamixRealworld dynamixNational instituteCare excellenceParticipating united kingdomWorld dynamixRheumatology insights

Spherix Research Reveals Rheumatologists Taking the Lead Over Nephrologists in Both BENLYSTA (GlaxoSmithKline) and LUPKYNIS (Aurinia) Patient Initiations in Lupus Nephritis

/PRNewswire/ With the approvals of GlaxoSmithKline s Benlysta in lupus nephritis (LN) at the end of 2020 and Aurinia s Lupkynis at the beginning of 2021,.

Novartis cosentyxRoche genentech gazyvaChemocentryx tavneosMaxine yarnallAurinia lupkynisGlaxosmithkline benlystaJanssen tremfyaOur servicesLaunch dynamixGlobal insightsRheumatology franchiseSpherix global insights

vimarsana © 2020. All Rights Reserved.